Slides
Page 1
Investor Presentation Q2FY26 30-10-2025 1
Page 2
DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks. The investor presentation is not intended to endorse, advertise, promote or recommend the use of any products listed in it which are for representation purpose only, some of which are reference listed drugs of which the Company has approved, under approval or under development generic equivalents. The prefixes “g” and “generic” used interchangeably indicate the generic versions of the named brand drugs. Information relating to any medical products or medical devices contained herein is provided by Cipla for general information purposes only. Information on any of the medical products or medical devices may vary from country-to-country. A reference to a medical product or a medical device does not imply that such medical product or medical device is available in your country. The commercial availability of the medical products or medical devices listed herein in your country is dependent on the validity and status of existing patents and/or marketing authorizations related to each. An independent enquiry regarding the availability of each medical products or medical device should be made for each individual country. The product information contained herein is not intended to provide complete medical information, and is not intended to be used as an alternative to consulting with qualified doctors or health care professionals. Nothing contained herein should be construed as giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important to only rely on the advice of a healthcare professional. 2
Page 3
Highest-Ever Quarterly Revenue at INR 7,500+ Cr with Robust Profitability 1. Market data as per IQVIA MAT Sep-25 | 2. Market data as per IQVIA week ended 19 th Sep’25 | 3. Market data as per IQVIA MAT Aug’25 Business Performance Snapshot Revenue EBITDA PAT INR 7,589 Cr 8% (YoY) INR 1,895 Cr INR 1,351 Cr $ 233 MnINR 3,146 Cr 5%$ 134 Mn $ 110 Mn 15% Foracort ranked #1 brand in the market1 Albuterol ranked #1 in the overall U.S. Albuterol MDI market2 with a market share of 22% SA Private growing at a market multiple3 of 1.3x Highest-Ever Quarterly revenue Q2FY26 (YoY) (YoY) One India North America One Africa Emerging Markets & Europe Q2FY26 25% of Revenue 18% of Revenue (YoY) (YoY) 3 7% (YoY) 0.5% 4%
Page 4
Financial Performance – Q2FY26 Revenue1 Break-up One India, 41% North America, 27% One Africa, 16% Emerging Markets & Europe, 13% API, 2% Others, 1% Revenue INR 7,589 Cr EBITDA INR 1,895 Cr Actuals (INR Cr) vs Q2 FY25 Total Revenue from Operations 7,589 7.6% EBITDA 1,895 0.5% EBITDA % 25.0% PAT 1,351 3.7% PAT % 17.8% Q2FY26 (Consolidated) R&D2 1. One India includes Rx + Gx + CHL; One Africa includes South Africa, North Africa, Sub -Saharan Africa and Cipla Global Access| 2. Opex including depreciation | 3. Total debt includes lease liabilities and borrowings| 4. Cash Balance includes current investments, fixed deposits, margin deposits and excluding unclaimed dividend balances | 5. Net Cash is Cash balance, net of Total Debts 7.1% of revenue 4 Balance Sheet Strength Sep-25 Total Debt3 Cash Balance4 Net Cash5 INR 467 Cr INR 10,368 Cr INR 9,901 Cr INR 539 Cr
Page 5
Branded Prescription ❖ Cipla maintained #2 market2 rank in overall Chronic ❖ Chronic mix improved to 61.8% ❖ Key therapies like Urology, Anti- diabetes, Cardiac, Anti-infectives and Dermatology outpaced the market2 growth Trade Generics ❖ Business delivered a strong growth during the quarter ❖ 2 Brands with TTM revenue of > INR 100 Cr and 5 Brands with TTM revenue of INR 50 Cr to INR 100 Cr ❖ 6 new launches in Q2 FY26, including entry into Orthocare to expand therapy coverage Consumer Health ❖ Delivered a robust growth with anchor & transitioned brands continuing to grow bigger ❖ Sustained EBITDA trajectory ❖ Nicotex3, Omnigel4 and Cipladine4 ranked #1 in the market One India1 - Committed to Sustainable Progress and Enduring Impact 1. India includes Branded Prescription, Trade Generics and Consumer Health| 2. Market data as per IQVIA MAT Sep’25| 3. Market data as per IQVIA Mar’25 | 4. Market data as per AC Neilsen MAT Apr’25 5 Delivered a Revenue of INR 3,146 Cr in Q2 FY26
Page 6
India Rx - Strengthening Our Journey with Strategic Therapeutic Focus 1. Market data as per IQVIA MAT Sep’25 22 Brands IPM1 Brands in Top 300 ranks Key Market Highlights IPM1 Brands with revenue > INR 100 Cr Steady Uptake in Key Therapies1 Growth (%) 6 Therapies With IPM1 Top 5 ranks 29 Brands #1 Foracort Biggest Brand in IPM1 6 Largest pharma company by Volume (units) in market1 4 Brands added in the category of market1 revenue > INR 100 Cr YoY Respiratory Supremacy, with Cipla's brands occupying all top 5 spots in the category1 29 Brands 13% 10% 17% 7% 8% 12% 8% 12% 4% 8% Cardiac Anti-diabetes Urology Anti-infectives Respiratory Market Growth Cipla Growth
Page 7
7 Unlocking Growth in Chronic Care: Cipla–Eli Lilly Collaboration Market Impact & Accessibility • Yurpeak- Available in KwikPen® Presentation • Pen Type: Multi-dose, single-patient-use prefilled pen • Doses per Pen: 4 fixed doses • Dosing Frequency: Once weekly • Available Strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg Product Availability & Dosage • Agreement Type: Promotion and Distribution • Product: Yurpeak (Tirzepatide) • Original Brand: Mounjaro (launched by Lilly) • Target Market: India • Pricing Strategy: Same Pricing as Mounjaro • Manufacturing Responsibility: Eli Lilly • Distribution & Promotion Responsibility: Cipla Key Highlights Product Indication • Expanded Reach: Partnership extends Tirzepatide availability beyond cities with Eli Lilly’s existing presence • Addressing Growing Health Concerns: ➢ ~101 Mn Indians with diabetes ➢ ~100 Mn Indians affected by obesity • Yurpeak introduces a new treatment option for these widespread conditions Indicated as an adjunct to diet and exercise for: • Type 2 Diabetes Treatment • Chronic Weight Management in adults with: ➢ Obesity (BMI ≥ 30) ➢ Overweight (BMI ≥ 27) + ≥1 weight- related comorbidity
Page 8
CLICK TO EDIT MASTER TITLE STYLE Empowering the Fight Against AMR: Cipla’s Stewardship Huena (Methenamine Hippurate) ❑ Cipla introduces HUENA® – India’s first non-antibiotic drug for recurring urinary tract infections ❑ HUENA - Long-term, low dose antibiotic therapy with lower costs and no risk of antibiotic resistance ❑ Promising substitute to long-term low dose antibiotics Zemdri (Plazomicin) ❑ Cipla strengthens fight against AMR, secures approval to introduce ZEMDRI® (plazomicin) injection in India ❑ Indicated for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis ❑ UTIs are a global health problem affecting approximately 150 million patients each year Cipenmet (Novel anti-infective) ❑ Cipla partners with Orchid Pharma to launch antibiotic Cefepime- Enmetazobactam in India, used in the treatment of cUTI, HAP and VAP indications1 ❑ Combines Orchid's innovative drug development capabilities with our extensive distribution network ❑ Enhanced commitment to AMR stewardship and deliver advanced, innovative therapies to patients 8 1. Urinary Tract infections (cUTI), Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP)
Page 9
9 Q2 FY26 - Global Consumer Wellness Franchise Skin Infection Pain Relief Hydration Nicotine Replacement Respi OTC Cold & Cough One India One Africa Consumer brands in One India Revenue: INR 404 Cr Consumer brands in South Africa Revenue: ZAR 437 Mn 2 2 2 1 1. Market ranks as per IQVIA Mar’25 | 2. Market ranks as per AC Neilsen Apr’25 |Above numbers exclude sales of wellness brands through prescription channel Respi OTC Cold & Cough 2 Pain Management Respi OTC
Page 10
North America - Witnessed Continuous Traction in Key Differentiated Assets • Albuterol ranked No. 1 in market1 with share increased to 22% (50 million+ inhaler units supplied to the U.S. market cumulatively) • Lanreotide market2 share increased to 22% during the quarter • Launched Filgrastim, our first biosimilar in the U.S. market • Our manufacturing facility in Bommasandra, Bengaluru, has been classified as VAI by the USFDA during the quarter Key Business Highlights 1. Market data as per IQVIA week ended 19th Sep’25 (No. 1 rank in overall U.S. Albuterol MDI market) | 2. Market data as per IQVIA MAT Aug’25 10 Pipeline Update • By Calendar year 2026, we expect to launch 4 major Respiratory assets, including gAdvair in Q4FY26, and 3 peptide assets, including Liraglutide. 3 out of 4 Respiratory assets are filed from our U.S. facilities which derisks these launches. Key Product Approval Glucagon for Injection USP, 1 mg/vial
Page 11
98 20 39 9 22 4 66 1 15 7 2 2 Approved ANDAs & NDAs Tentatively Approved ANDAs & NDAs Under Approval ANDAs & NDAs Cipla Ltd PEPFAR Invagen Partnered ANDAs/NDAs ANDA & NDA Portfolio & Pipeline (As on 30th September 2025) 1. PEPFAR approved ANDAs can be commercialised in U.S. 180 Approved ANDAs & NDAs 45 Tentatively Approved ANDAs & NDAs 60 Under Approval ANDAs & NDAs 285 Total ANDAs & NDAs 1 11
Page 12
1,197 1,341 1,398 Q2FY24 Q2FY25 Q2FY26 One Africa1 - South Africa Private Growing 1.3x Faster than the Market 1. One Africa - South Africa, North Africa, Sub-Saharan Africa (SSA) and Cipla Global Access (CGA) | 2. Market data as per IQVIA MAT Aug’25 In the prescription market2 SA Ranked #2 Across multiple therapies in H1 FY26 6 new launches SA Key Highlights2 9 brands with MAT market revenue > 100 Mn ZAR Healthy performance across key therapies like Respiratory, CNS and Anti-infectives SA Private Revenue trendZAR Mn Highest number of brands in top 30 (8), top 50 (11) and top 100 (20) within generics segment 12 Market Segment 2 Rank Share Cipla Growth Market Growth South Africa Prescription 2 8.7% 8.3% 6.1% South Africa OTC 3 8.4% 2.4% 2.2% South Africa Overall 3 8.6% 6.2% 4.7% 75 80 20 23 9 11 23 21 Q2FY25 Q2FY26 SA Private SA Tender North Africa Others (SSA & CGA)
Page 13
Q2FY26 - Emerging Markets & Europe and API Emerging Markets & Europe API 13 96 110 Q2FY25 Q2FY26 Revenue 19 17 Q2FY25 Q2FY26 Revenue
Page 14
14 Goals (India Manufacturing Operations by 2025) Progress as on YTD Aug 2025 80% reduction in absolute Scope 1 (energy based) and Scope 2 emissions from baseline year of FY 2019-20 76% reduction from the baseline year, YTD Aug 2019 Water neutrality Achieved 1.75 times water positive, as on FY 2025 Zero Waste to Landfill (‘ZWTL’) All Cipla India Manufacturing operations are ZWTL certified, as on FY 2025 50% renewable electricity 55% renewable electricity Continuing zero fatality in our manufacturing operations Zero Fatality Full compliance with safe discharge targets established by AMR Industry Alliance Achieved full compliance with the safe discharge targets. Two AMR certified product - Azithromycin Dihydrate and Ciprofloxacin Achievement and Recognition Cipla’s case study on Energy Transition is selected in SB COP and will be featured in a special digital booklet in Nov 2025. The Sustainable Business COP (SB COP) is a global initiative led by the Brazilian National Confederation of Industry (CNI), designed to enhance and formalize the private sector's role in global climate negotiations, within the framework of the UNFCCC. MSCI ESG Rating – Upgraded to A from BBB Q2FY26: Progress on ESG goals (India Manufacturing Operations) 14
Page 15
Consolidated Profit and Loss Statement Summary Note : Figures have been rounded-off 15 Particulars Q2 FY26 Q2 FY25 Revenue from sale of products 7,447 6,961 Other operating income 142 90 Income from operations 7,589 7,051 Material cost 2,498 2,283 Employee benefits expense 1,315 1,208 Other expenses 1,882 1,675 Total expenses 5,695 5,165 Finance costs 13 15 Depreciation, impairment and amortization expense 297 272 Other income 269 191 Profit before exceptional items and tax 1,854 1,789 Profit before tax 1,854 1,789 Tax expenses 500 483 Share of associate 0 -1 Profit for the period 1,353 1,305 Non-controlling interest 2 2 Profit for the period attributable to shareholders 1,351 1,303 INR Cr
Page 16
Consolidated Balance Sheet #Total debt includes lease liabilities and borrowings | * Cash & cash equivalents include current investments, fixed deposits, margin deposits and excluding unclaimed dividend balances |Figures have been rounded-off 16 Key Balance Sheet Items Sep-25 Sep-24 Equity 33,025 28,456 Total Debt# 467 461 Inventory 6,160 5,573 Cash and Cash Equivalents* 10,368 8,412 Trade Receivables 6,902 5,588 Trade Payables 3,035 2,675 Net Tangible Assets 6,996 6,329 Goodwill and Intangibles 5,374 5,111 INR Cr
Page 17
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Diksha Maheshwari Investor.Relations@cipla.com For more information please visit www.cipla.com 17